## EFX: Equifax Inc. - XLI: Industrials

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (38% of avg), momentum weakening (-2.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($211.05)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Equifax Announces Earnings Release Date and Conference Call for Fourth Quarter 2024 Results**
- Source: Quantisnow | 20251223T100757 | Neutral | Relevance: 100%
- Equifax (NYSE: EFX) will release its fourth quarter 2024 financial results on Thursday, February 6, 2025, at 6:30 a.m. ET. The company will then host a conference call at 8:30 a.m. ET to discuss these results. Related presentation materials will be available on their investor relations website.

**2. Equifax acquires HR services firm Vault Verify**
- Source: MSN | 20251222T180801 | Bullish | Relevance: 100%
- Equifax has acquired Vault Verify, an HR services firm that offers employment and income verification services. This acquisition aims to enhance Equifax's Workforce Solutions business, expanding its client base and service offerings in a rapidly evolving HR landscape dominated by technology and data analytics.

**3. Squarepoint Ops LLC Sells 179,251 Shares of Equifax, Inc. $EFX**
- Source: MarketBeat | 20251222T220755 | Neutral | Relevance: 100%
- Squarepoint Ops LLC significantly reduced its stake in Equifax, selling 179,251 shares and retaining only 4,031 shares. This move aligns with recent insider selling activity, including CEO Mark W. Begor's sale of over 21,000 shares. Despite the institutional selling, Equifax reported strong Q3 earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating.

**4. Q3 Earnings Roundup: Equifax (NYSE:EFX) And The Rest Of The Data & Business Process Services Segment**
- Source: Yahoo Finance | 20251223T090825 | Somewhat-Bearish | Relevance: 95%
- This article reviews the Q3 earnings for the data & business process services sector, highlighting strong revenue beats across the board and an average 4.8% stock increase since earnings reports. It details individual company performances, with Equifax (EFX) posting mixed results despite revenue growth, Planet Labs (PL) showing the strongest performance with significant revenue growth and analyst beats, and Verisk (VRSK) delivering the weakest results. The article also touches on market conditions, including recent interest rate cuts and a strong stock market performance in 2024.

**5. Verisk (VRSK) Expands KYND Cyber Partnership: A Fresh Look at Whether the Stockâ€™s Valuation Still Stacks Up**
- Source: Simply Wall Street | 20251225T001210 | Neutral | Relevance: 65%
- Verisk Analytics (VRSK) has strengthened its cyber risk intelligence offerings by expanding its partnership with KYND, integrating richer data into its Rulebook platform, amid increasing UK retail cyber vulnerabilities. Despite this strategic move and double-digit earnings growth, Verisk's recent share price performance has been weak, even though a "Most Popular Narrative" suggests the stock is 12.9% undervalued. The article questions whether Verisk is a mispriced compounder or if its growth story is already fully factored into its valuation, noting its high P/E ratio compared to the industry average.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $280 | $290 | -3% |
| 2025-12-08 | BMO Capital | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Overweight |
| 2025-12-08 | BMO Capital | main | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.90M) |
| Sells | 5 ($1.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+2.1%)
- Capital Internationa: 8.5% (-0.4%)
- Blackrock Inc.: 7.5% (+1.4%)
- Price (T.Rowe) Assoc: 4.9% (+1.0%)
- Harris Associates L.: 4.8% (+14.2%)

### Key Risks

1. Long-term trend broken: trading 8.8% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.2B |
| Beta | 1.59 |
| 52W Range | $199.98 - $281.07 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 25.0 |
| Current P/E | 29.0 |
| YoY Growth | 16.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.5% to 1.4% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >4.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (0.96), confirming momentum. RSI neutral at 59. Volume at 38% of 20MA suggests lack of conviction. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.38% (CS: 71) | Neutral |
| RSI_14 | 58.8 | Neutral |
| MACD Histogram | 0.96 | Bullish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 1.024x | Above |
| vs SMA200 | 0.912x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $220.63
- **Stop Loss:** $211.05 (4.3% risk)
- **Target:** $239.79 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 93
- **Position Value:** $20,518.59
- **Portfolio %:** 20.52%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-05 (Est: $2.04)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.94 | $2.04 | +5.3% |
| 2025Q2 | $1.92 | $2.00 | +4.1% |
| 2025Q1 | $1.40 | $1.53 | +9.0% |
| 2024Q4 | $2.10 | $2.12 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*